Ratings Ono Pharmaceutical Co., Ltd.

Equities

4528

JP3197600004

Market Closed - Japan Exchange 02:00:00 2024-04-19 am EDT 5-day change 1st Jan Change
2,238 JPY -2.76% Intraday chart for Ono Pharmaceutical Co., Ltd. -5.97% -11.05%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • With a P/E ratio at 8.15 for the current year and 9.67 for next year, earnings multiples are highly attractive compared with competitors.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
-11.05% 6.99B
B+
+20.91% 43.54B
B-
+16.96% 21.74B
B+
+9.05% 13.53B -
+7.98% 13.02B
B+
+33.80% 11.28B
B
-0.05% 6.79B - -
-8.87% 5.73B - -
+6.64% 5.09B
B+
+3.49% 4.42B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4528 Stock
  4. Ratings Ono Pharmaceutical Co., Ltd.